We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Novel Immune Cells Play a Crucial Role in the Severity of Asthma

A person holds an asthma inhaler in front of their mouth.
Credit: CNordic Nordic/ Unsplash
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

 Researchers at McMaster University have made an important discovery in the field of asthma research, identifying a new population of immune cells that may play a crucial role in the severity of asthma symptoms. 


The study, published in Science Translational Medicine on Jan. 15, 2025, sheds light on the complex mechanisms behind severe asthma and opens new avenues for potential treatments.


Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to difficulty breathing. Severe asthma, which affects up to 10 per cent of the general asthma population, is particularly challenging to treat due to its resistance to standard therapies. 


“When you can’t breathe, nothing else matters,” says Roma Sehmi, senior and corresponding author of the paper and professor in the Department of Medicine at McMaster University. “Our Hamilton-based group has been world leaders in evaluating the type of inflammation in the airways using methods developed to sample and examine sputum. We sought to better understand the mechanisms behind severe asthma so that we can better treat these patients.”


The research team recruited patients from St. Joseph’s Healthcare Hamilton and carried out experimental work in laboratories within McMaster University and the Firestone Institute for Respiratory Health (FIRH), a joint McMaster University-St. Joseph’s research institute.


Researchers explored a unique group of immune cells in the airways of people with severe asthma. The cells, called c-kit+IL-17A+ ILC2s, can be likened to chameleons; they can change their characteristics and have traits of two different types of immune cells. The study found that these "intermediate ILC2s" are linked to the presence of two types of cells that cause inflammation and make asthma worse (eosinophils and neutrophils).


The researchers discovered that people with severe asthma have these chameleon-like ILC2s that show markers of another cell type, ILC3, which are associated with a high number of neutrophils in the airways – often seen in difficult-to-treat severe asthma. The study also found growth factors that encourage the formation of these intermediate ILC2s, suggesting that controlling their levels could prevent too many neutrophils from accumulating and worsening asthma symptoms. 

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
The ability of ILC2s to change and take on features of ILC3s in the airways of asthma patients is a new discovery. This finding gives new insights into what drives severe asthma and points to potential new treatment targets. By understanding the role of these intermediate ILC2s, researchers hope to develop better treatments for patients with severe asthma who don't respond well to current therapies.


“When asthma is associated with both eosinophils and neutrophils cells, individuals are generally less responsive to treatment with glucocorticosteroids – which are the mainstay of treatment for severe asthma. The findings from this research pave the way for discovering new therapeutic targets for difficult-to-treat asthma,” said Parameswaran Nair, co-corresponding author of the paper and professor in the Department of Medicine at McMaster University. 


Reference: Ju X, Fard NE, Bhalla A, et al. A population of c-kit+ IL-17A+ ILC2s in sputum from individuals with severe asthma supports ILC2 to ILC3 trans-differentiation. Sci Transl Med. 2025;17(781):eado6649. doi: 10.1126/scitranslmed.ado6649


This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.